anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.

Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrodantin and other antibacterial drugs, Macrodantin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrodantin are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrodantin, other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrodantin, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized.
The invention provides application of a begonia water extract in preparing a medicine for treating hyperuricemia and gout. The results show that the main components of the Malus spectabilis tea water extract can effectively reduce the blood uric acid, the joint uric acid level and the liver xanthine oxidase activity of rats ( P<0.05 or P<0.01 ). IC of phlorizin on xanthine oxidase 50 Is (355.2 +/-1.78) mu g/mL, and belongs to mixed inhibition in reversible competitive inhibition. Phloretin IC 50 Is (123.4 +/-1.03) mu g/mL and is competitiveReversible inhibition. Trihydroxyphlorizin IC 50 Is (2.02 +/-1.79) mu g/mL, and belongs to the anti-competitive reversible inhibition. The phlorizin and phloretin have synergistic effect on the inhibition of xanthine oxidase. The crabapple tea and the main components of phlorizin, phloretin and trihydroxyphlorizin can regulate the uric acid metabolism by inhibiting the activity of xanthine oxidase and other ways, and have the effect of preventing and treating hyperuricemia and gout.
Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
PURPOSE:A drug effective for remedying and preventing chicken coccidiosis caused by the parasitism of coccidium protozoan especially belonging to the genus Eimeria, and coccidiosis of turkey, duck, etc., comprising flenolicin B as an active ingredient. CONSTITUTION:The titled coccidiostat comprising flenolicin B, a compound shown by the formula, as an active ingredient. In methods for using it, it is used alone or by a common method in an agent form such as dust, granule, tablet, powder, capsule, etc. together with a proper carrier. A carrier which is ued as a drug for feed is usable as the carrier, and lactose, starch, wheat flour, maize, wheat bran, lees of soybean oil, fish meal, pressed lees of peanut, etc. may be cited as the carrier. The medication concentration of the active ingredient is usually 0.0005-0.05wt% preferably 0.002-0.2wt% based on feed. The agent is properly blended to satisfy the amount and medicated.
CMV retinitis is a common opportunistic infection in patients with AIDS. Ganciclovir is currently the only drug approved for treatment of CMV retinitis in immunocompromised patients. Ganciclovir suppresses CMV infections, and relapse occurs in virtually all AIDS patients when ganciclovir is discontinued. Because of their similar hematologic (blood) toxicities, the simultaneous use of ganciclovir and zidovudine (AZT) is not recommended. More recently the drug foscarnet has become available for investigational use. Studies so far indicate that remission of CMV retinitis occurs in 36 to 77 percent of patients, and that relapse occurs in virtually all patients when the drug is discontinued. The relative effectiveness of foscarnet compared with ganciclovir for the immediate control of CMV infections is unknown. Further, the long-term effects of foscarnet or ganciclovir on CMV retinitis, survival, and morbidity are unknown. There is also no definitive information on the relative effectiveness and safety of deferred versus immediate treatment for CMV retinitis confined to zones 2 and 3.

Patients are assigned to one of two groups: (1) Patients with any retinitis in zone 1 or patients with retinitis involving 25 percent or more of zones 2 and 3; and (2) Patients in whom retinitis is confined to less than 25 percent of zones 2 and 3 of the retina. Half the patients in group 1 get immediate treatment with ganciclovir; the other half receive immediate treatment with foscarnet. Patients in group 2 are treated with foscarnet or ganciclovir either immediately or treatment is deferred. If patients in group 2 have strong preferences regarding when therapy is instituted, they may elect immediate treatment or deferral of treatment.
PROBLEM TO BE SOLVED: To receive the suitable control of biological risk due to the expert of medical treatment or health care by measuring the biological data of a healthy person or a patient at home by himself/herself at home, checking the measured biological data of himself/herself and easily transmitting these data to the side of host such as a medical treatment institution or health care center with a portable telephone as a medium. SOLUTION: An A type adapter 1A for biological control is composed of a sensor part 5 and a MODEM 2 and enables the measurement of body temperature, electrocardiograph and heart rate. A flexible rod 4 is provided with an electrode 5a and the sensor part 5 of a thermistor 5e at the tip end part and housed in the housing part of MODEM 2 so as to be freely stretched. The measurement of electrocardiograph is performed by a power supply switch 3, clock set button 6 and electrodes 5a-5c. Further, a measuring button 7, transmission button 8, display part 9 and a plug 10 for connection to the portable telephone are provided. Through these measuring means and transmitting means, biological risk control can easily be received with the portable telephone as the medium.
Research participants will have access to the web-based platform for 7 to 14 days prior to receiving a second, identical series of self-report surveys assessing stigma, empowerment, and knowledge of opioids. Additionally, after using the platform, research participants will complete a measure of system usability.
Pamidronate Disodium is a sterile bone-resorption inhibitor available in 30 mg and 90 mg vials for intravenous administration. The pamidronate disodium obtained by combining pamidronic acid and sodium hydroxide is provided in a sterile, ready to use solution for injection. Each mL of the 30 mg vial contains, 3 mg Pamidronate Disodium, 47 mg Mannitol, USP; Water for Injection, USP, q.s.; Phosphoric acid to adjust pH. Each mL of the 90 mg vial contains, 9 mg Pamidronate Disodium, 37.5 mg Mannitol, USP; Water for Injection, USP, q.s.; Phosphoric acid to adjust pH. The pH of a 1% solution of pamidronate disodium in distilled water is approximately 8.3. Pamidronate, a member of the group of chemical compounds known as bisphosphonates, is an analog of pyrophosphate. Pamidronate disodium is designated chemically as phosphonic acid (3-amino-1-hydroxypropylidene) bis-, disodium salt, and its structural formula is:

Pamidronate disodium is soluble in water and in 2N sodium hydroxide, sparingly soluble in 0.1N hydrochloric acid and in 0.1N acetic acid, and practically insoluble in organic solvents. Its molecular formula is C3H9NO7P2Na2 and its molecular weight is 279.1 (calculated as the anhydrous form).

Inactive Ingredients: Mannitol, Phosphoric acid (for adjustment to pH range of 6.0 to 7.0) and Water for Injection.
PURPOSE: A cosmetic composition containing bee venom or bee venom extract is provided to improve anti-oxidation, anti-aging, and anti-wrinkle. CONSTITUTION: A cosmetic composition contains bee venom or bee venom extract as an active ingredient. The content of the bee venom or bee venom extract is 0.0001-30 weight%. The venom extract is isolated using water, organic solvent or mixture solvent thereof. The organic solvent is ethanol, methanol, butanol, ether, ethyl acetate, or chloroform. The mixture solvent is 10-90%(v/v) ethanol.
A group of 12 subjects presenting a normal weight and a group of 12 obese subjects, with a good general health and a good dental state will be constituted. They will participate to 5 different recording sessions during which they will be invited to chew and spit out foods and chewing gums of different hardness. During recording sessions with mastication and no-mastication periods, gas exchange (O2 concentration), cardiac activity (electrocardiography) and muscular activity of masticatory muscles (electromyography) will be recorded. Blood samples will be collected during one of the sessions to analyse the kinetic of appearance of some hormones in the blood compartment during or just after mastication. The selected hormones are involved in the eating behaviour and its regulation (ghrelin, peptide C, peptide YY and glucose-like peptide 1). From these recordings, energy expenditure, heart rate variability, intensity of masticatory muscle contraction, and hormone blood appearance will be analysed in link with the nature and hardness of the food chewed. Since the food bolus is spit out after mastication (without any swallowing = sham-feeding), the changes observed in theses variables will be directly attributed to sensory information coming from oral cavity during mastication. Food choice and sport activity of each volunteer will be taken into account to compare the results obtained for the two groups (normal weight and obese).

The work will produce more data and evidence on the contribution of oral signals attributable to the food in the regulation of the energy balance. The results will also bring more knowledge on the involvement of the autonomic nervous system. Comparison of the results obtained for the two groups (normal weight and obese people), will bring some positive outcomes which could be useful in the fight against obesity.
The method for treating demodecosis of the face comprises the clinical examination, the laboratory detection of the causative agent, diagnosing and the treatment. The foamy solution for the treatment is prepared ex tempore from 3.0-10.0 of the liquid soap, 1.5-15 mL of 3 % hydrogen peroxide, and 1.0-5.0 mL of 10 % ethanolic ammonia solution. The mixture is stirred with the brush until foaming and applied onto the affected skin for 20-30 min once a week. The remainder of the foam is washed out with water. The result is assessed in several hours. When necessary, the treatment is repeated up to 10 times until the clinical effect.
In the context of routine care, 3 blood collection will be performed on adult sickle cell patients for the analysis of hemoglobin fractions. For each blood collection, an additional volume of blood will be taken for the research purposes.
Unlike adult mammals, the hearts of neonatal mice possess the ability to completely regenerate from myocardial infarction (MI). This observation has sparked vast interest in deciphering the potentially lifesaving and morbidity-reducing mechanisms involved in neonatal cardiac regeneration. In mice, the regenerative potential is lost within the first week of life and coincides with a reduction of Insulin-like growth factor 1 receptor (Igf1r) expression in the heart. Igf1r is a well-known regulator of cardiomyocyte maturation and proliferation in neonatal mice. To test the role of Igf1r as a pivotal factor in cardiac regeneration, we knocked down (KD) Igf1r specifically in cardiomyocytes using recombinant adeno-associated virus (rAAV) delivery and troponin T promotor driven shRNAmirs. Cardiomyocyte specific Igf1r KD versus control mice were subjected to experimental MI by permanent ligation of the left anterior descending artery (LAD). Cardiac functional and morphological data were analyzed over a 21-day period. Neonatal Igf1r KD mice showed reduced systolic cardiac function and increased fibrotic cardiac remodeling 21 days post injury. This cardiac phenotype was associated with reduced cardiomyocyte nuclei mitosis and decreased AKT and ERK phosphorylation in Igf1r KD, compared to control neonatal mouse hearts. Our in vivo murine data show that Igf1r KD shifts neonatal cardiac regeneration to a more adult-like scarring phenotype, identifying cardiomyocyte-specific Igf1r signaling as a crucial component of neonatal cardiac regeneration.
Ablation strategy for persistent AF besides pulmonary vein isolation remains controversial. Indeed, two approaches have prevailed over the past two decades "cox-maze" strategy and mapping of the left atrium but both methods have failed to decrease AF recurrences (as shown by the clinical trial STAR AF 2). Two studies have demonstrated that the ligament of Marshall (LOM) could be the source of focal activities, the substrate of reentries and a strong parasympathetic modulator. For these reasons, LOM may represent a major target in AF treatment besides PV isolation. Nevertheless, conventional ablation techniques do not ensure the complete destruction of Marshall's musculature and parasympathetic ganglia that surround it, largely isolated by a sheath of adipose tissue. To overcome this technical limitation, LOM elimination can be achieved by alcohol injection into the vein of Marshall.The investigator innovative approach called Marshall Plan will then consists in 3 steps: 1) the destruction of Marshall bundles by ethanol infusion followed by the ablation of the distal Coronary Sinus (CS) bundles, the ridge and the saddle; 2) the standard PV isolation; 3) and finally ablation of the mitral line, the roof and of the cavo-tricuspid isthmus, main causes of recurrence in atrial flutter.

Before ablation procedure patients will be randomized in 2 arms: Marshall Plan (treatment arm) or pulmonary vein isolation (control arm). Patients will be followed at 3, 6, 9 and 12 months in-office visits or hospitalization. Patients will have different tests: electrocardiogram (ECG), cardiac echography, stress test, 24hours Holter and transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.
Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Previous research has shown that (ACEs) are associated with negative health outcomes, including depression, problematic alcohol use, and disordered patterns of overeating, including food addiction (FA). Moreover, anhedonia, or an inability to feel pleasure, has been also shown to increase risk for problematic alcohol use, as well as FA. It is possible that anhedonia may be implicated in health risk behaviors as individuals with anhedonia may seek out highly hedonic activities. The purpose of the present study was to explore the direct and indirect relationship between ACEs and alcohol use disorder (AUD) and FA symptoms via anhedonia in a diverse sample of emerging adults with histories of heavy drinking. A cross-sectional, quantitative design was used. The sample was 42.6% male, 45.5% White, and 39.9% Black, and the average age of participants was 22.64 (SD = 1.01). A confirmatory factor analysis was used to specify the model, and structural equation modeling was used to test the hypotheses. The initial measurement model was overidentified and demonstrated acceptable to favorable fit. Standardized results from a bootstrap analysis of the structural regression model showed significant direct effects of ACEs on FA and AUD symptoms. Results also found a significant indirect effect of ACEs on AUD symptoms through anhedonia, though this indirect effect was not significant for FA. Anhedonia could be a key target for the prevention and treatment of problematic alcohol use. Future research should examine the role of anhedonia in the maintenance of FA in nonheavy drinking samples. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to development of agents with extrogenic anticlimacterium effect. Proposed agent has Conium maculatum C6, Glonoinum C3, Lachesis mutus C6, Sanguinaria canadensis C3, Zincum valerianicum C6 and Pilocarpus jaborandi C3 being all components are taken in equal parts. Agent can be made as sugar granules. Treatment with proposed agent results to improvement of the general state of patient, neurotic symptoms are disappeared and replaced with equilibrium behavior, headache is disappeared, patients have sense of quiet assurance and comfort. EFFECT: enhanced effectiveness of drug. 2 cl
The invention discloses one and treat parotitic plaster, weigh following medical material according to parts by weight: Plumbum preparatium 45-55g, Rumalus sophorae 80-120g, Fructus Gleditsia branch 75-85g, Fructus Gleditsia acupuncture 60-80g, Ramulus Mori 80-100g, ailanthus altissima (mill.) swingle branch 80-120g, Oleum sesami 80-120g. The preparation method of this plaster comprises the steps: first to explode Rumalus sophorae, Fructus Gleditsia branch, Fructus Gleditsia acupuncture, Ramulus Mori, ailanthus altissima (mill.) swingle branch after boiled for Oleum sesami, pulls out and make medicine oil after 3-5min; Then mix with Plumbum preparatium and be brewed into jelly, cool down 1-2min; Finally being coated on special cloth or fabric by this jelly, separate with gauze, there is sticking cloth at two ends, are processed into plaster. The present invention with various natural Chinese medicines materials for raw material, wide material sources, prove through several clinical trials, being used for treating parotitis cure rate is 90%. Instant effect of the present invention, effective, have no side effect, easy to use.
GAD is among the most common anxiety disorders in the elderly population. The drug lorazepam is widely utilized in the treatment of elderly individuals with GAD. However, single doses of lorazepam have been associated with cognitive toxicity that is typically evident between 1 and 2.5 hours after the drug is administered. The toxic effects include decreased memory and increased swaying, which has been associated with greater risk for falls.

Patients have 4 study visits. A psychiatric evaluation and a memory test are given at the first visit. During the second study visit, patients have a physical exam, an electrocardiogram (ECG), a neuropsychological assessment, an optional magnetic resonance imaging (MRI) brain scan, and other laboratory tests. On the third and fourth visits, patients are randomized to receive either their highest daily dose of lorazepam or placebo. Performance effects and postural sway are determined before drug administration and at 1, 2.5, and 5 hours after the drug is given. Blood samples for the determination of drug levels are also obtained.
The invention discloses a thousand-mesh traditional Chinese medicine preparation used for controlling livestock and poultry diarrhea, and a preparation method thereof. The preparation is prepared from mixed Chinese herbal medicines of, by weight: 6 to 11 parts of amur corktree bark, 6 to 11 parts of pericarpium arecae, 6 to 11 parts of radix gentianae, 8 to 15 parts of tuckahoe, 8 to 15 parts of eclipta prostrate, 3 to 5 parts of asiatic plantain seed, 3 to 5 parts of purslane, and 2 to 4 parts of manyleaf meadowrue root. The preparation provided by the invention is characterized in that: the preparation is prepared from pure Chinese medicines, and the formulation is reasonable. The preparation is formulated according to the principles of heat clearing, detoxificating, dampness dissipating, and diarrhea relieving with astringents. Different formulations show different pharmacologic actions. With the medicine formula provided by the invention, effects of root cause and symptom treating, healthy energy supporting, evil eliminating, comprehensive regulating, and yin-yang balancing can be achieved. The preparation provided by the invention provides substantial effects on livestock and poultry diarrhea caused by various factors, and provides a curative effect greatly higher than those of simple recipe medicines and other western medicine preparations. The preparation has advantages of wide sources of raw materials of Chinese herbal medicines, low cost, high recovery rate, no drug residue, no toxic or side-effect, and wide application range.
Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
The invention relates to a traditional Chinese medicine for the adjuvant therapy of hypnotic poisoning. The invention develops a pure traditional Chinese medicine compound preparation according to the Chinese medicine theory, the experience of the medical circle, the clinical experience of the inventor and the modern pharmacological knowledge of the traditional Chinese medicine. The invention mainly aims at the therapy of a patient suffering from hypnotic poisoning by the alimentary canal, and eliminates a weak link of the residual toxin of the intestinal canal. By the clinical application of many years, the traditional Chinese medicine obtains a better therapy effect. The traditional Chinese medicine is characterized by the effects of strong cathartic function, toxin adsorption, toxin expelling, detoxification and emiction assistance. The traditional Chinese medicine is better than other cathartic methods adopted clinically, and has a leading superiority in the technique. The formula of the traditional Chinese medicine comprises rhubarb, talcum, raw rhizome of cyrtomium, aloe, tea leaves, senna, raw liquorice, raw mung bean, and the like. The invention is compound decocted decoction with professional production in a bottling mode, and every bottle contains 250 milliliters. After gastric lavage, a patient suffering from hypnotic poisoning orally takes the compound decocted decoction or is infused with the compound decocted decoction of 250-1000 milliliters every time according to an illness condition.